Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-11-27
Disclosure Type: Major Management Matters Related to Investment Decisions
💡 3-Second Summary
Alteogen is set to receive a milestone payment of USD 15,000,000 (approx. KRW 21.9B) within 30 days, as Keytruda SC (a subcutaneous formulation utilizing Alteogen’s ALT-B4) has successfully obtained marketing authorization in Europe from global pharmaceutical giant MSD.
📊 1. [Summary of Core Disclosure Content and Key Figures]
- Recipient and Amount: Alteogen is scheduled to receive USD 15,000,000 (approx. KRW 21.9B) in milestone payments under the license agreement for ‘ALT-B4 (ingredient name: berahyaluronidase alfa)’ with MSD International Business GmbH (MSD).
- Condition and Background: The milestone was triggered by achieving marketing authorization in Europe for ‘Keytruda SC’ (subcutaneous injection formulation), which incorporates Alteogen’s ALT-B4 technology.
- Financial Scale: The milestone payment amount exceeds 10% of Alteogen’s consolidated revenue from the previous year (approx. KRW 102.9B).
- Foreign Exchange Rate Base: The applied standard foreign exchange rate is KRW 1,462.70/USD, based on the Seoul Foreign Forex Brokerage market average rate on November 27, 2025.
- Payment Timeline and Conditions: The payment is expected to be received within 30 days from the invoice issuance date (2025-11-27). Alteogen has no obligation to return the milestone payment even if the contract terminates.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This disclosure serves as direct validation that Alteogen’s proprietary technology, ALT-B4, has advanced into the commercialization phase in Europe, one of the largest global healthcare markets. Beyond a simple one-time cash inflow, this non-refundable payment equivalent to over 10% of the previous year’s total annual revenue could have a positive potential impact on the company’s short-term financial structure and liquid cash flow.
In particular, as this milestone stems from the European approval of Keytruda SC—a subcutaneous version of a global blockbuster drug—it can be interpreted as a significant turning point that may lead to long-term changes in the company’s core business Fundamental, such as potential future commercial royalties and commercialization milestones in other global regions.
📝 Editor’s Comment (by K-STOCK Editor)
A high-certainty milestone at the ‘final regulatory approval stage’ has now materialized for this biotech firm. While the partner’s identity was masked as a trade secret in the original 2020 contract, the February 2024 amendment officially disclosed the counterpart as ‘MSD’ and the target as ‘Keytruda SC.’ This subsequent European approval provides solid proof that Alteogen’s SC formulation platform technology has successfully cleared the stringent hurdles of global regulatory bodies. The influx of non-refundable cash is expected to further fortify the company’s financial stability.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!